IA方案与维奈克拉联合MA方案在初治急性髓系白血病患者中的应用效果  

Application effect of IA regimen and venclexta combined with MA regimen in patients with newly diagnosed acute myeloid leukemia

作　　者：田文亮[1] 王萌[1] 邢海洲[1] TIAN Wenliang;WANG Meng;XING Haizhou(Department of Hematology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China)

机构地区：[1]郑州大学第一附属医院血液内科,郑州4500000

出　　处：《癌症进展》2025年第7期770-773,共4页Oncology Progress

基　　金：河南省2022年科技发展计划项目(222102310172)。

摘　　要：目的比较去甲氧柔红霉素^(+)阿糖胞苷(IA)方案与维奈克拉联合米托蒽醌^(+)阿糖胞苷(MA)方案在初治急性髓系白血病(AML)患者中的应用效果。方法根据治疗方法的不同将100例初治AML患者分为观察组(n=49,维奈克拉联合MA方案治疗)和对照组(n=51,IA方案治疗)。比较两组患者的临床疗效、血常规指标[白细胞计数(WBC)、血小板计数(PLT)、血红蛋白(Hb)]、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))及不良反应发生情况。结果观察组患者的总有效率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者WBC、CD8^(+)水平均降低,PLT、Hb、CD4^(+)水平及CD4^(+)/CD8^(+)均升高,观察组患者WBC、CD8^(+)水平均低于对照组,PLT、Hb、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者不良反应总发生率低于对照组,差异有统计学意义(P﹤0.05)。结论与IA方案相比,维奈克拉联合MA方案治疗初治AML患者的临床疗效更好,还可改善血常规指标和免疫功能,减少不良反应的发生。Objective To compare the the application effect of idarubicin^(+)cytarabine(IA)regimen and venclexta combined with mitoxantrone^(+)cytarabine(MA)regimen in patients with newly diagnosed acute myeloid leukemia(AML).Method According to different treatment methods,100 patients with newly diagnosed AML were divided into observation group(n=49,venclexta combined with MA regimen treatment)and control group(n=51,IA regimen treatment).The clinical efficacy,blood routine indexes[white blood cell count(WBC),platelet count(PLT),hemoglobin(Hb)],immune function indexes(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and adverse reactions were compared between the two groups.Result The total effective rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the levels of WBC and CD8^(+)were decreased in both groups,while the levels of PLT,Hb,CD4^(+)and CD4^(+)/CD8^(+)were increased in both groups,the levels of WBC and CD8^(+)in observation group were lower than those in control group,while the levels of PLT,Hb,CD4^(+)and CD4^(+)/CD8^(+)were higher than those in control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion Compared with IA regimen,venclexta combined with MA regimen has better clinical efficacy in the treatment of newly treated AML patients,and can also improve blood routine indexes and immune function,and reduce adverse reactions.

关 键 词：急性髓系白血病 米托蒽醌 维奈克拉 临床疗效 不良反应 

分 类 号：R733.7[医药卫生—肿瘤]